Fumapharm is a privately held pharmaceutical company headquartered in Lucerne, Switzerland. FUMADERM, an oral product containing fumaric acid esters, was approved in Germany in 1994 where it is the leading prescription for oral systemic treatment of severe psoriasis. Fumedica GmbH distributes FUMADERM in Germany.
Fumapharm AG was acquired by Biogen on May 31, 2006.
Join Mergr to view all 120 acquisitions of life science companies in 2006, including 22 acquisitions by private equity firms, and 98 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2006. The largest life science acquisition in 2006 was Guidant - which was acquired by Boston Scientific for $24.6B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Fumapharm AG.
No obligation. Cancel anytime.